We consume proteins everyday - they help to keep us strong & healthy. Cytonic products contain the specific protein required to feed our immune cells, VDTP. In our ISO and GMP registered laboratory, we extract VTDP from bovine colostrum and then filter it many, many times until only the proteins remain—there is absolutely no casin present. Let’s take a look at what cytonic products comprise of and how theyregulate immune system function. Cytoproteins (cyto meaning cell) are proteins that activate cells. There are 482 cytoproteins on the vitamin D transport protein chain and each activates a specific type of cell in our body. Feeding our immune cells is one very important function of Cytoproteins, another major function is the transport of vitamins & fatty acids o build and repair cells as well as removing toxins from the body. This vital function earns the name 'transport protein' |
What is a transport protein? |
VDTP is a multifunctional transport protein produced by the human body. It is responsible for transporting vitamin D, binding fatty acids, removing toxins, and a range of other roles associated with immune system modulation and inflammatory responses. It contains 482 cytoproteins interwoven into 3 domains with 3 important functions. |
Domain 1 – Vitamin D bindingVitamin D promotes calcium absorption, modulates cell growth, contributes to neuromuscular and immune function, and reducest inflammation. Every cell in our bodies has a vitamin D receptor, and every cell in our body secretes a vitamin D hormone. Vitamin D transport protein binds the vitamin D already stored in the body and transports it to where it is most needed. Domain 2 – Fatty acid bindingFatty acids are required for many vital human body functions from building healthy cells to maintaining brain and nerve function. Because our bodies can’t produce all the fatty acids we require, we must receive some of them through food. VDTP binds these essential fatty acids and transports them to where they can help our cells heal and repair. Domain 3 – Actin ScavengerVDTP is an important component of the plasma actin scavenger system and acts like a refuse collector transporting these toxins from the lymphatic system, blood stream, tissues, and bones to the liver so that they can be naturally eliminated from the body. Within this 3rd domain of VDTP functions, we find a cluster of cytoproteins designed to activate our immune cells. It is this cluster that first drew the attention of renowned immunologist Dr. Nobuto Yamamoto, who discovered that this specific cluster is responsible for activating our white blood cells into becoming natural killer cells, B-cells, and macrophages. |
Inactive immune cells |
![]() |
Natural Killer cells |
![]() |
B-cells |
They also act as a beacon, signalling danger to natural killer cells. B-cells prevent cells from becoming infected, but if they do become infected, natural killer cells move in and destroy the infected cell. This leads us onto our 3rd, and most potent immune cell—the macrophage. |
Macrophages |
Opsonin “super glue” helps them stick to their prey. Their electron-driven free radical death ray (AKA “oxidative burst”) blasts holes in microbes and cancer cells. Once a microbe or cancer cell has been phagocytized by a macro, it is encapsulated inside a “phagolysosome” (the intracellular “death chamber”), where it is then killed (if it isn’t dead already). The phagolysosome then secretes a cocktail of corrosive free radicals and enzymes that rapidly digest the pathogen down into its component parts conisting of amino acids, nucleic acids & fatty acids. Because these are fundamental cellular building blocks, the body quickly recycles them using the “spare parts” to build brand new healthy cells. |
Nagalase – a little known enemy of the immune system |
Before Dr. Yamamoto’s research on nagalase, immunosuppression caused by viruses and tumors was poorly understood. Yamamoto discovered that cancer patients had high levels of nagalase, and that this enzyme destroyed (deglycolylated) the cluster of cytoproteins on the VDTP chain required to activate our immune cells. Nagalase has no natural enemies, and no bodily process, drug, or treatment could outsmart it. Dr. Yamamoto’s research on this enzyme has led to our modern-day understanding of what causes immunosuppression, allowing cancers to grow and viruses to multiply unchecked. Without access to this cluster of cytoproteins, which is found only on VDTP, activation of natural killer cells, B- cells, and macrophages is nearly impossible. Therefore, Dr Yamamoto began to focus on finding a way to outsmart nagalase. Before Dr. Yamamoto’s research on nagalase, immunosuppression caused by viruses and tumors was poorly understood. Yamamoto discovered that cancer patients had high levels of nagalase, and that this enzyme destroyed (deglycolylated) the cluster of cytoproteins on the VDTP chain required to activate our immune cells. Nagalase has no natural enemies, and no bodily process, drug, or treatment could outsmart it. Dr. Yamamoto’s research on this enzyme has led to our modern-day understanding of what causes immunosuppression, allowing cancers to grow and viruses to multiply unchecked. Without access to this cluster of cytoproteins, which is found only on VDTP, activation of natural killer cells, B- cells, and macrophages is nearly impossible. Therefore, Dr Yamamoto began to focus on finding a way to outsmart nagalase. |
Finding Immunity from Nagalase |
|
The first human trials of GcMAF |
![]() A few years later Dr. Yamamoto repeated this trial of injeted GcMAF with patients who were HIV positive; these patients also showed elevated levels of nagalase. By the end of the trial, negalase levels in all patients were also found within the normal range, giving injectable GcMAF a very positive track record. Despite this revolutionary approach to stimulating immune system function and three successful human trials to support his theories, Dr. Yamamoto’s work had not received the accolades or even attention that it deserved. As a means of protecting his work, Yamamoto patented the process of GcMAF production and the nagalase test. He could not, however, patent VDTP because it is a naturally occurring protein or its derivative GcMAF. |
Dr. Bradstreet’s pioneering work with GcMAF and autism |
|
The evolution of GcMAF to Cytonics |
Cytoinnovations Ltd. have been researching and developing GcMAF products since 2011. In 2015, we tasked our scientists with the goal of using GcMAF to engineer VDTP to function, not only to activate monocytes into becoming macrophages, but also to activate our lymphocytes - all in the presence of nagalase. This, we hoped, would facilitate quicker responses by lymphocytes and more harmonious immune function overall. Although macrophages are probably our most versatile immune cells, they are not as effective against viruses as our natural killer cells or B-cells. When natural killer cells and macrophages are activated together, macrophages revert to a secondary role, cleaning the battlefield of dead pathogens and cancer cells and then recycling their components to build new healthy cells. For this and several other reasons, we believed that splicing the protein cluster responsible for macrophage activation would lead to a product that would be far more effective than the original GcMAF, and we weren’t disappointed.
|